

Pharmacy & Therapeutics Committee (P&T) Meeting

Colorado Department of Health Care Policy & Financing (HCPF)

Date, Time	Tuesday, January 6, 2026	1:00-5:00 PM MST
Location	Virtual: Webinar link will be available on January 5th	

Agenda

1. Call to Order and Welcome

- Quorum Confirmation
- Introductions

2. Old Business

- Approval of meeting minutes from October 7th, 2025, P&T meeting
- Updates from October 7th, 2025, P&T meeting

3. New Business

- Updates from the Prior Authorization Call Center

4. Review Process

- Full Review:
 - Oral presentation by manufacturers, providers, and public
 - Overview for each Drug Class, including market share overview.
 - Committee Discussion and Recommendations for each Drug Class
- Mass Review:
 - Overview for each Drug Class, including market share overview.

5. Drug Class Reviews

A Full Review:

- Anticonvulsants – Oral
- Atypical Antipsychotics – Oral & Topical
- Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Neurocognitive Disorder Agents
- Newer Generation Antidepressants
- Stimulants and Related Agents
- Skeletal Muscle Relaxants
- Triptans, Ditans and Other Migraine Treatments – Oral & Non-Oral
- Ophthalmics:
 - Glaucoma
 - Immunomodulators

B Mass Review:

- Anti-Parkinson's Agents
- Anxiolytics – Non-Benzodiazepines
- Benzodiazepines (Non-Sedative Hypnotic)
- Fentanyl Preparations (Buccal, Transmucosal, Sublingual)

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf



Agenda

- Lithium Agents
- Monoamine Oxidase Inhibitors (MAOIs)
- Multiple Sclerosis Agents
- Non-Opioid Analgesia Agents – Oral & Topical
- Non-Steroidal Anti-Inflammatories (NSAIDs) – Oral & Non-Oral
- Ophthalmics:
 - Allergy
 - Anti-Inflammatories (NSAIDs, Corticosteroids)
- Opioids – Short-Acting & Long-Acting
- Sedative Hypnotics (Benzo & Non-Benzo)
- Tricyclic Antidepressants (TCAs)

6. Presentation Requests & Stakeholder Comment Guidelines (Including Manufacturers)

- Each request must include a one-page clinical summary focused solely on clinical information (no cost, anecdotal, or economic data) and relevant only to products under PDL review.
- Presentations are limited to verbal comments with no visual aids except designated handouts.
- Approved presentations and written comments will be provided to the Committee in advance of the meeting.
- Submit requests no later than **December 31, 2025, at 5:00 PM MST** to:
Mohamed Duklef, Clinical Program Manager-mohamed.duklef@medimpact.com
CC: Greg Miller, PDL & Clinical Strategy Pharmacist – greg.l.miller@state.co.us
- For full stakeholder comment policies, visit the [P&T Committee Policies & Procedure](#) page.

7. Adjourn

- Upcoming Meeting Date: **April 7th, 2026**

Accessibility

Reasonable accommodation will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator at hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.